본문으로 건너뛰기
← 뒤로

Cancer survival in Italian patients diagnosed between 2008 and 2017.

1/5 보강
Cancer epidemiology 2026 Vol.101() p. 103001
Retraction 확인
출처

Capocaccia R, Fusco M, Zarcone M, Fruscione S, Pesce MT, Stracci F, Mazzucco W, Graziano G, Mazzola S, Minichino A, Sessa A, Tumino R, Colanino AZ, Candela G, Loperto I, Vitale F, Abbate R, Clemente SV, Vincenzi R, Piras D, Porcheddu A, Gasparotti C, Maifredi G, Pinna P, Zollo E, Ciullo V, Baracco S, Napolioni V, Manasse S, Eugenia S, Usticano A, Caldarella A, Turi A, Santelli E, Galasso R, Riccio LD, Martinelli L, Mantovani W, Serraino D, Maso LD, Ferrante M, Migliore E, Leite S, Villa M, Casella C, Russo AG, Negrino L, D'orsi G, Manzoni F, Bruni R, Castelli M, Gambino M, Cavallo R, Fametti AC, Ghisleni S, Sampietro G

📝 환자 설명용 한 줄

As national cancer survival estimates in Italy date back to 2011, we provided updated figures using population-based cancer registries.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Capocaccia R, Fusco M, et al. (2026). Cancer survival in Italian patients diagnosed between 2008 and 2017.. Cancer epidemiology, 101, 103001. https://doi.org/10.1016/j.canep.2026.103001
MLA Capocaccia R, et al.. "Cancer survival in Italian patients diagnosed between 2008 and 2017.." Cancer epidemiology, vol. 101, 2026, pp. 103001.
PMID 41653505

Abstract

As national cancer survival estimates in Italy date back to 2011, we provided updated figures using population-based cancer registries. Analyses by age and sex included 1.418.044 cancers diagnosed between 2013 and 2017 from 34 registries covering 48 million residents. The 2008-2017 period, with 20 registries covering 24 million residents, was used for trends and regional comparisons. Net survival was estimated by Pohar-Perme method with life tables by year, sex, residence and calculated using the international standard distribution. Five-year age-standardized net survival for all cancers combined was 66.7 % in females and 62.2 % in males. Females had better survival than males for most cancers, notably acute lymphatic leukaemia (+9 % points (pp)), upper respiratory/digestive (+9 pp), lung (+6 pp), CNS (+5 pp), and stomach (+4 pp). Males had a higher survival for bladder (+4 pp), kidney (+2 pp), and urinary cancers (+5 pp). Best outcomes (>75 %) were documented for prostate, testicular, breast, endometrial, thyroid, melanoma, Hodgkin lymphoma, bladder, and chronic lymphatic leukaemia. Poorest prognosis (<30 %) was for CNS, liver, lung, pancreas, and acute myeloid leukaemias. Survival was age-dependent, highest in younger and lowest in older patients, with > 40 % points gaps in some haematological cancers. From 2008-2017, net survival arose from 65.7 % to 70.7 % in men and from 69.9 % to 74.1 % in women. Improvements were seen for pancreas, lung, and acute leukaemias, mainly in women, while decreases affected bladder, cervical, chronic lymphatic leukaemia in men. Geographical disparities persisted, with higher survival in Northern-Central Italy (64.0 % for men and 68.3 % for women) than in Southern-Islands (58.1 % for men and 63.7 %, for women). Our findings confirmed a better prognosis for younger patients and females than male patients. Survival has continued to improve over time, even at a higher improving rate in the considered period than the past.

MeSH Terms

Humans; Male; Female; Italy; Middle Aged; Aged; Neoplasms; Adult; Registries; Young Adult; Aged, 80 and over; Adolescent; Child, Preschool; Child; Infant; Prognosis; Survival Rate; Infant, Newborn